Free Biopharma Daily Stock Updates - 08/09/21

$XBI $127.53 +0.20%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

COVID Updates

$SRNE +4.2% Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program source

$MRNA +17.1% Australian Therapeutic Goods Administration Grants Provisional Registration for Moderna’s COVID-19 Vaccine source

$INO +5.4% INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate. source

Pipeline Updates

$FLXN -4.4% Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA) source

$TCON +4.4% TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial. source

$HRMY -0.6% Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other Rare Neurological Diseases. source

$IMPL +16.7% Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal Headache. source

$VYGR +6.0% Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform TechnologiesVoyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies. source

$ADMA -1.9% ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM® and NABI-HB®. source

$AUTL +2.5% Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL. source

$AXSM -46.5% Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression. source

$TRIL -2.4% Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia. source

$ARAV +2.9% Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma. source

$EGRX +4.5% Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker. source

$AZN -0.0% Forxiga approved in the EU for the treatment of chronic kidney disease in patients with and without type-2 diabetes. source

$AZN 0.0% Enhertu significantly improved progression-free survival in DESTINY-Breast03 head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer . source

$CALT +0.9% Calliditas Receives FDA Fast Track Designation for setanaxib in PBC. source

$HCM +2.4% HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China. source

Financial Updates

$BCRX +0.2% BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants source

$AQST +3.2% Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant™ Related Capital Under Current Debt Agreement. source

---

Posted by FS/JM